Linda M. Liau

Linda M. Liau

Auto-generated profile, based on publicly available information

Linda M. Liau

Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2009 in Nature
Verified
Journal Article
Open access
PDF file
LDLenny Dang
Lenny Dang
DWDavid W. White
David W. White
SGStefan Gross
Stefan Gross
BBBryson D. Bennett
Bryson D. Bennett
MBMark A. Bittinger
Mark A. Bittinger
SSShinsan M. Su
Shinsan M. Su
Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature of a major subset of primary human brain cancers. These mutations occur at a single amino acid residue of the IDH1 active site, resulting in loss of the enzyme’s ability to catalyse conversion of isocitrate to α-ketoglutarate. However, only a single copy of the gene is mutated in tumours, raising the possibility that the mutations do not result in a simple loss of function. Here we show that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). Structural studies demonstrate that when arginine 132 is mutated to histidine, residues in the active site are shifted to produce structural changes consistent with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert α-ketoglutarate to 2HG. Excess accumulation of 2HG has been shown to lead to an elevated risk of malignant brain tumours in patients with inborn errors of 2HG metabolism. Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG. These data demonstrate that the IDH1 mutations result in production of the onco-metabolite 2HG, and indicate that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.

11 February 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCTimothy F Cloughesy
Timothy F Cloughesy
AMAaron Y. Mochizuki
Aaron Y. Mochizuki
JOJoey R. Orpilla
Joey R. Orpilla
WHWilly Hugo
Willy Hugo
ALAlexander H. Lee
Alexander H. Lee
RPRobert M. Prins
Robert M. Prins

10 November 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
IMIngo K. Mellinghoff
Ingo K. Mellinghoff
MWMaria Y. Wang
Maria Y. Wang
Igor VivancoIgor Vivanco
Igor Vivanco
DHDaphne A. Haas-Kogan
Daphne A. Haas-Kogan
SZShaojun Zhu
Shaojun Zhu
PMPaul S. Mischel
Paul S. Mischel
The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to EGFR kinase inhibitors. The mechanism of responsiveness of glioblastomas to these inhibitors is unknown. We sequenced kinase domains in the EGFR and human EGFR type 2 (Her2/neu) genes and analyzed the expression of EGFR, EGFR deletion mutant variant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients who had received EGFR kinase inhibitors. We determined the molecular correlates of clinical response, validated them in an independent data set, and identified effects of the molecular abnormalities in vitro. Of 49 patients with recurrent malignant glioma who were treated with EGFR kinase inhibitors, 9 had tumor shrinkage of at least 25 percent. Pretreatment tissue was available for molecular analysis from 26 patients, 7 of whom had had a response and 19 of whom had rapid progression during therapy. No mutations in EGFR or Her2/neu kinase domains were detected in the tumors. Coexpression of EGFRvIII and PTEN was significantly associated with a clinical response (P<0.001; odds ratio, 51; 95 percent confidence interval, 4 to 669). These findings were validated in 33 patients who received similar treatment for glioblastoma at a different institution (P=0.001; odds ratio, 40; 95 percent confidence interval, 3 to 468). In vitro, coexpression of EGFRvIII and PTEN sensitized glioblastoma cells to erlotinib. Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors.

1 June 2017 in Cancer Cell
Verified
Journal Article
Closed access
FCFlorence M.G. Cavalli
Florence M.G. Cavalli
MRMarc Remke
Marc Remke
LRLadislav Rampasek
Ladislav Rampasek
JPJohn Peacock
John Peacock
DSDavid J.H. Shih
David J.H. Shih
MTMichael D. Taylor
Michael D. Taylor

20 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
IBIvo Buchhalter
Ivo Buchhalter
AMA. Sorana Morrissy
A. Sorana Morrissy
VHVolker Hovestadt
Volker Hovestadt
JWJoachim Weischenfeldt
Joachim Weischenfeldt
PLPeter Lichter
Peter Lichter
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.

11 December 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RBRameen Beroukhim
Rameen Beroukhim
GGGad Getz
Gad Getz
LNLeia Nghiemphu
Leia Nghiemphu
JBJordi Barretina
Jordi Barretina
THTeli Hsueh
Teli Hsueh
WSWilliam R. Sellers
William R. Sellers
Comprehensive knowledge of the genomic alterations that underlie cancer is a critical foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to analyze cancer genomes are underway, but the analysis is hampered by the lack of a statistical framework to distinguish meaningful events from random background aberrations. Here we describe a systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer. We use it to study chromosomal aberrations in 141 gliomas and compare the results with two prior studies. Traditional methods highlight hundreds of altered regions with little concordance between studies. The new approach reveals a highly concordant picture involving ≈35 significant events, including 16–18 broad events near chromosome-arm size and 16–21 focal events. Approximately half of these events correspond to known cancer-related genes, only some of which have been previously tied to glioma. We also show that superimposed broad and focal events may have different biological consequences. Specifically, gliomas with broad amplification of chromosome 7 have properties different from those with overlapping focalEGFRamplification: the broad events act in part through effects onMETand its ligandHGFand correlate with MET dependencein vitro. Our results support the feasibility and utility of systematic characterization of the cancer genome.